Advertisement

„Low-dose“-Theophyllin zur Prävention von Exazerbationen bei COPD-Patienten – Eine sinnvolle Therapie?

  • Timm GreulichEmail author
Journal Club
  • 3 Downloads

Originalpublikation

Devereux G, Cotton S, Fielding S et al (2018) Effect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with COPD—a randomized clinical trial. JAMA 320(15):1548–1559.  https://doi.org/10.1001/jama.2018.14432

Zusammenfassung der Studie

Hintergrund.

Die chronisch obstruktive Lungenerkrankung (COPD) spielt weltweit eine zunehmende Rolle. Für ihre Morbidität und Mortalität sind v. a. die akuten Exazerbationen von Bedeutung, die im Rahmen ihrer Behandlung auch die meisten Kosten verursachen. Zur COPD-Therapie wird oft das breit verfügbare und vergleichsweise preiswerte Theophyllin in hoher Dosis verwendet. Laut präklinischen Untersuchungen verstärken jedoch bereits niedrige Plasmakonzentrationen dieses Wirkstoffs (1–5 mg/l) die antiinflammatorischen Effekte von Kortikosteroiden bei COPD und könnten demzufolge für die Prävention von Exazerbationen von Bedeutung sein.

Studiendesign.

Bei TWICS („theophylline with inhaled corticosteroids“)...

Low-dose theophylline for prevention of exacerbations in COPD patients—A meaningful treatment?

Notes

Interessenkonflikt

T. Greulich hat von CSL-Behring, DZL und Grifols Forschungsunterstützung erhalten. Für Astra Zeneca, Berlin-Chemie, Ingelheimer, Chiesi, CSL-Behring, Grifols, GSK und Novartis hat er Vorträge gehalten oder an Advisory Boards und Kongressen teilgenommen.

Literatur

  1. 1.
    Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D (2018) Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet.  https://doi.org/10.1016/S0140-6736(18)30206-X
  2. 2.
    Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ, Investigators I (2018) Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med 378:1671–1680CrossRefGoogle Scholar
  3. 3.
    Wedzicha JA, Rabe KF, Martinez FJ, Bredenbroker D, Brose M, Goehring UM, Calverley PM (2013) Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest 143:1302–1311CrossRefGoogle Scholar
  4. 4.
    Vogelmeier C, Buhl R, Burghuber O, Criee CP, Ewig S, Godnic-Cvar J, Hartl S, Herth F, Kardos P, Kenn K, Nowak D, Rabe KF, Studnicka M, Watz H, Welte T, Windisch W, Worth H (2018) unter Mitwirkung der folgenden wissenschaftlichen Fachgesellschaften: Deutsche Gesellschaft fur Arbeitsmedizin und Umweltmedizin e V, Deutsche Gesellschaft fur Rehabilitationswissenschaften e V: [Guideline for the Diagnosis and Treatment of COPD Patients—Issued by the German Respiratory Society and the German Atemwegsliga in Cooperation with the Austrian Society of Pneumology. Pneumologie 72:253–308CrossRefGoogle Scholar
  5. 5.
    Cosio BG, Iglesias A, Rios A, Noguera A, Sala E, Ito K, Barnes PJ, Agusti A (2009) Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of chronic obstructive pulmonary disease. Thorax 64(5):424–429CrossRefGoogle Scholar
  6. 6.
    Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ (2004) Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 200:689–695CrossRefGoogle Scholar
  7. 7.
    Barnes PJ (2013) Theophylline. Am J Respir Crit Care Med 188:901–906CrossRefGoogle Scholar
  8. 8.
    Ford PA, Durham AL, Russell RE, Gordon F, Adcock IM, Barnes PJ (2010) Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 137:1338–1344CrossRefGoogle Scholar
  9. 9.
    Zhou Y, Wang X, Zeng X, Qiu R, Xie J, Liu S, Zheng J, Zhong N, Ran P (2006) Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 11:603–610CrossRefGoogle Scholar
  10. 10.
    Cosio BG, Shafiek H, Iglesias A, Yanez A, Cordova R, Palou A, Rodriguez-Roisin R, Peces-Barba G, Pascual S, Gea J, Sibila O, Barnes PJ, Agusti A (2016) Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial. Chest 150:123–130CrossRefGoogle Scholar
  11. 11.
    Devereux G, Cotton S, Fielding S, McMeekin N, Barnes PJ, Briggs A, Burns G, Chaudhuri R, Chrystyn H, Davies L, De Soyza A, Gompertz S, Haughney J, Innes K, Kaniewska J, Lee A, Morice A, Norrie J, Sullivan A, Wilson A, Price D (2018) Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial. JAMA 320:1548–1559CrossRefGoogle Scholar
  12. 12.
    Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF (2015) Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 385:857–866CrossRefGoogle Scholar
  13. 13.
    Vestbo J (2016) the Salford Lung Study I: Effectiveness of Fluticasone Furoate-Vilanterol in COPD. N Engl J Med 375:2607CrossRefGoogle Scholar
  14. 14.
    Buhl R, Criee CP, Kardos P, Vogelmeier C, Lossi N, Mailander C, Worth H (2016) A year in the life of German patients with COPD: the DACCORD observational study. Int J Chron Obstruct Pulmon Dis 11:1639–1646CrossRefGoogle Scholar
  15. 15.
    Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID (2015) Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 3:435–442CrossRefGoogle Scholar
  16. 16.
    Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, Wedzicha JA, Singh D (2015) Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 192:523–525CrossRefGoogle Scholar
  17. 17.
    Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fageras M (2018) Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med 6(2):117–126CrossRefGoogle Scholar
  18. 18.
    Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2019 report). www.goldcopd.org/gold-reports/

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Innere Medizin, SP PneumologieUKGM MarburgMarburgDeutschland

Personalised recommendations